Become A Featured Company

MariMed Inc. Reports Record Third Quarter 2017 Financial Results

Ryan Allway

November 15th, 2017

News

Financial Highlights

  • REVENUE:  Increase of 96% compared to same quarter in 2016; 110% increase for nine-month period compared to the same period in 2016.
  • OPERATING INCOME:  Increase of five times compared to same quarter in 2016.
  • EBITDA*:  Increase of more than three times compared to same 2016 quarter; year-to-date total of $1,361,000 is over four times higher than the nine-month 2016 period.
  • TOTAL ASSETS:  Increase to $21,372,000, marking the second quarter in a row of 28+% sequential quarter-to-quarter asset growth; 149.6% increase in assets since December 31, 2016.

Operating Highlights

  • CONSUMER BRANDS: Distribution of Kalm Fusion™ product line expanded to 51 of the 52 licensed state dispensaries in Illinois, in addition to dispensaries in Delaware and Rhode Island.
  • CLINICALLY-PROVEN MEDICAL STRAINS: Doubled sales of Tikun Olam flower products in Delaware since the initial Q2 offering which the Company leveraged to obtain exclusive license to distribute Tikun Olam’s clinically proven medical cannabis strains in Rhode Island, Maryland, Massachusetts and Illinois in 2018.
  • STATE OPERATIONS:  Continued major progress to build out a national presence in the rapidly growing cannabis business:
    • Existing Revenue Producing Operations
      • Delaware:  MariMed customer First State Compassion’s New Lewes dispensary open for a full quarter, increasing monthly revenues by approximately 50%, with still further growth anticipated.
      • Illinois: Expanded distribution of the Kalm Fusion™ product line to nearly all licensed dispensaries and inclusion of the newly acquired Betty’s Eddies™ line.
    • Future Revenue Producing Operations
      • Nevada:  Our Las Vegas cultivation facility progressed from our Q2 permit to operate to beginning cultivation in Q3 with expected first revenues in late Q4 of 2017 / Q1 of 2018.
      • Maryland:  Hagerstown cultivation facility received certificate of occupancy in Q3 with grow approval expected in Q4 and expected first revenues in Q1 of 2018.  Dispensary site located in Annapolis, with purchase anticipated to close in Q1 of 2018, with first revenues shortly thereafter.
      • Massachusetts:  Purchase of Middleboro dispensary facility, with expected first revenues in Q1 of 2018, with sites for two more dispensaries in process.  Extended the contract to purchase 137,500 square foot industrial building on 17 acres for a production and cultivation facility in New Bedford, with expected first revenues in Q2 of 2018 (purchase of site concluded in Q4 as a subsequent event to Q3).
      • Other States:  Consulting services for strategic partners to secure cultivation and dispensary licenses in additional states, based on a clear regulatory framework and finding the right partners.

NEWTON, Mass., Nov. 15, 2017 (GLOBE NEWSWIRE) —  MariMed Inc. (OTCQB:MRMD), a leading provider of cannabis facility management services, branded consumer products, and clinically proven medical strains, today reported financial results for the third quarter ending September 30, 2017.

“Successful development of our consumer and medical brands is one of our key strategies for long term profitable growth,” said Robert Fireman, MariMed Chairman and Chief Executive Officer. “In Q3, we achieved significant distribution gains and saw significant market uptake for Kalm Fusion, our new Betty’s Eddies, and the Tikun Olam clinically-proven medical strains.  We are aggressively pursuing expansion to markets where we have facilities coming online and to other markets in distribution agreements, where we assure manufacturing to uniform quality standards.”

Jon Levine, MariMed Chief Financial Officer, commented on the Company’s significant asset expansion, as follows: “MariMed is one of the few companies in the U.S. cannabis industry delivering on a commitment for rapid, high quality, multi-state expansion.  Our business model and strong financial results enable us to secure the necessary capital to build our national presence in owned facilities and production agreements for licensed brands.  In Q3, the Company delivered milestone achievements on multiple state facilities and expanded brand distribution that will translate to significant new revenue streams in calendar 2018.”

The Company’s record financial results come from strong progress across all three of MariMed’s strategic business units:

i) Advisory and Management Services  – assisting applicants to secure state licenses, and then management, design, development and operation of cultivation, production and dispensing facilities for licensed cannabis operators;

ii) Real Estate Development – securing, development, and leasing of real estate to licensed cannabis operators; and

iii) Branded Cannabis Products  – delivering precision dosed cannabis-infused, branded products sold via licensing agreements with strategic partners from state to state such as MariMed’s Kalm Fusion line of products.

* Beginning this quarter, MariMed is supplementing the metrics of Revenue, Operating Income, and others prepared in accordance with generally accepted accounting principles (“GAAP”) with the non-GAAP financial metric of EBITDA.  EBITDA is equal to the Company’s operating income before interest, taxes, depreciation, and amortization.  Management uses EBITDA to assess the Company’s operational performance and liquidity.  EBITDA is not intended to be a substitute for the financial information prepared in accordance with GAAP, however we believe that both management and investors benefit from referring to EBITDA in assessing the results and financial health of the Company.

MariMed’s full financial statement is available at http://www.sec.gov/Archives/edgar/data/1522767/000149315217012999/form10-q.htm.

About MariMed Inc.:

MariMed designs, develops, finances, and optimizes medical cannabis cultivation, production, and dispensary facilities as a management service.  MariMed’s team has developed or is in the process of developing state-of-the art regulatory-compliant facilities in DE, IL, NV, MD, MA and RI.   These facilities are models of excellence in horticultural principals, cannabis production, product development, and dispensary operations. In addition, MariMed is on the forefront of precision dosed branded products for the treatment of specific medical symptoms.  MariMed currently distributes its branded products in select states and is expanding licensing and distribution to numerous additional states encompassing thousands of dispensaries.  MariMed Inc., is one of the 17 top-performing public cannabis companies in the U.S. tracked on the U.S. Marijuana Index, (www.marijuanaindex.com). For additional information, visit www.MarimedAdvisors.com

 

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading